Ads
related to: drospirenone indications for diabetes 1 and 2- Request a Rep & Samples
Visit HCP Site to Request a
Mayne Pharma Representative.
- Why NEXTSTELLIS®
Learn More About NEXTSTELLIS®
& Its Tolerability. Visit HCP Site.
- HCP Resources & Support
Find FAQs & Downloadable
Resources for You & Your Patients.
- Dosing & Prescribing
Learn More About Starting
Your Patients on NEXTSTELLIS®.
- Request a Rep & Samples
Search results
Results from the WOW.Com Content Network
[1] [5] [66] Drospirenone has antigonadotropic and functional antiestrogenic effects as a result of PR activation. [1] [73] The ovulation-inhibiting dosage of drospirenone is 2 to 3 mg/day. [76] [77] [1] [78] Inhibition of ovulation occurred in about 90% of women at a dose of 0.5 to 2 mg/day and in 100% of women at a dose of 3 mg/day. [79]
[2] [3] A formulation with levomefolic acid (vitamin B 9) has also been marketed (brand names Beyaz, Safyral, others), with similar indications. [7] [8] EE/DRSP is marketed widely throughout the world. [9] In 2022, it was the 142nd most commonly prescribed medication in the United States, with more than 4 million prescriptions. [10] [11]
Type 2 diabetes is the most common type of diabetes. Treatments include agents that (1) increase the amount of insulin secreted by the pancreas, (2) increase the sensitivity of target organs to insulin, (3) decrease the rate at which glucose is absorbed from the gastrointestinal tract, and (4) increase the loss of glucose through urination.
Estetrol is available in combination with drospirenone in the following formulations, brand names and indications: [citation needed] Estetrol (as monohydrate) 15 mg and drospirenone 3 mg Nextstellis (CA, US and Australia) – combined oral contraception
Drospirenone/estetrol, sold under the brand name Nextstellis, among others, is a fixed-dose combination medication containing drospirenone, a progestin, and estetrol, an estrogen, which is used as a combined birth control pill for the prevention of pregnancy in women. [2] [6] It is taken by mouth. [2] [6]
The study, which was published in Nature Medicine on January 20, analyzed data from more than 2 million people with diabetes who took GLP-1 receptor agonist medications like Ozempic and Wegovy.
Ads
related to: drospirenone indications for diabetes 1 and 2